BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34816496)

  • 1. The influence of age on prostate cancer screening index.
    Shan J; Liu Z; Geng X; Feng Y; Yang X; Xu H; Zhou X; Ma W; Zhu H; Shi H
    J Clin Lab Anal; 2022 Jan; 36(1):e24098. PubMed ID: 34816496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of prostate volume on clinical parameters in prostate cancer screening.
    Shan J; Geng X; Lu Y; Liu Z; Zhu H; Zhou R; Zhang Z; Gang X; Zhang D; Shi H
    J Clin Lab Anal; 2022 Oct; 36(10):e24700. PubMed ID: 36098911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.
    Zou BZ; Wen H; Luo HJ; Luo WC; Xie QT; Zhou MT
    Ir J Med Sci; 2023 Dec; 192(6):2681-2687. PubMed ID: 37414978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
    Nan LB; Yin XT; Gao JP
    Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer.
    Zhang Q; Li H; Song Z; Kong S; Zhao S; Fan S; Qin F; Ma J
    J Int Med Res; 2023 Oct; 51(10):3000605231204429. PubMed ID: 37848343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of TPSA, free to total PSA ratio and PSA density in prostate carcinoma diagnostics.
    Milkovic B; Hadzi-Djokic J; Dzamic Z; Pejcic T
    Acta Chir Iugosl; 2007; 54(4):105-7. PubMed ID: 18595240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
    Maeda H; Arai Y; Okubo K; Aoki Y; Okada T; Maekawa S
    Int J Urol; 1998 Jul; 5(4):343-8. PubMed ID: 9712442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
    Sakai I; Harada K; Hara I; Eto H; Miyake H
    Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical research analysis based on prostate cancer screening diagnosis.
    Shan J; Geng X; Liu Z; Lu Y; Zhou R; Zhang Z; Xu H; Zhou X; Ma W; Zhu H; Shi H
    Andrologia; 2022 May; 54(4):e14371. PubMed ID: 35014705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.